Hottest Stocks
(Over $10)
Hottest Stocks
($2-$10)
Biggest Losers
(Over $10)
Biggest Losers
($2-$10)
Hottest
Industries
Hottest
Sectors
EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Lifevantage Corporation (LFVN : NSDQ)
 
 • Company Description   
Lifevantage Corporation is a health and nutrition company. The company is the maker of Protandim(R), the Nrf2 Synergizer(R) patented dietary supplement, the TrueScience(TM) Anti-Aging Skin Care Regimen, Canine Health and the AXIO(TM) energy product line. Lifevantage Corporation is headquartered in Salt Lake City, Utah.

Number of Employees: 238

 
 • Price / Volume Information   
Yesterday's Closing Price: $7.40 Daily Weekly Monthly
20 Day Moving Average: 159,888 shares
Shares Outstanding: 12.70 (millions)
Market Capitalization: $93.99 (millions)
Beta: 0.22
52 Week High: $27.38
52 Week Low: $6.66
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week -17.41% -19.57%
12 Week -45.15% -47.42%
Year To Date -57.79% -63.10%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
3300 N. TRIUMPH BLVD SUITE 700
-
LEHI,UT 84043
USA
ph: 801-432-9000
fax: 801-880-0699
reed.anderson@icrinc.com http://www.lifevantage.com
 
 • General Corporate Information   
Officers
Steven R. Fife - Chief Executive Officer; President
Raymond B. Greer - Chairman
Rajendran Anbalagan - Director
Michael A. Beindorff - Director
Dayton Judd - Director

Peer Information
Lifevantage Corporation (ITRJ)
Lifevantage Corporation (BRLI.)
Lifevantage Corporation (GOGY)
Lifevantage Corporation (PSTX.)
Lifevantage Corporation (ELGXQ)
Lifevantage Corporation (CAH)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED/DENTAL-SUPP
Sector: Medical
CUSIP: 53222K205
SIC: 2834
Fiscal Year
Fiscal Year End: June
Last Reported Quarter: 09/01/25
Next Expected EPS Date: 02/04/26
Share - Related Items
Shares Outstanding: 12.70
Most Recent Split Date: 10.00 (0.14:1)
Beta: 0.22
Market Capitalization: $93.99 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 2.43%
Current Fiscal Quarter EPS Consensus Estimate: $0.22 Indicated Annual Dividend: $0.18
Current Fiscal Year EPS Consensus Estimate: $1.06 Payout Ratio: 0.22
Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: -0.10
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: 09/08/2025 - $0.05
Next EPS Report Date: 02/04/26  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 6.98
Trailing 12 Months: 8.92
PEG Ratio: -
Price Ratios
Price/Book: 2.83
Price/Cash Flow: 6.73
Price / Sales: 0.41
EPS Growth
vs. Year Ago Period: 20.00%
vs. Previous Quarter: 5.88%
Sales Growth
vs. Year Ago Period: 0.73%
vs. Previous Quarter: -13.70%
ROE
09/30/25 - 33.52
06/30/25 - 33.75
03/31/25 - 34.67
ROA
09/30/25 - 15.81
06/30/25 - 15.26
03/31/25 - 15.24
Current Ratio
09/30/25 - 2.39
06/30/25 - 1.87
03/31/25 - 1.66
Quick Ratio
09/30/25 - 1.30
06/30/25 - 1.11
03/31/25 - 0.98
Operating Margin
09/30/25 - 4.82
06/30/25 - 4.66
03/31/25 - 4.58
Net Margin
09/30/25 - 4.43
06/30/25 - 4.29
03/31/25 - 4.12
Pre-Tax Margin
09/30/25 - 5.20
06/30/25 - 5.36
03/31/25 - 5.65
Book Value
09/30/25 - 2.61
06/30/25 - 2.75
03/31/25 - 2.71
Inventory Turnover
09/30/25 - 2.23
06/30/25 - 2.32
03/31/25 - 2.45
Debt-to-Equity
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - 0.00
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©